Full Generic Medicine Info
Dosage/Direction for Use

Relapsing forms of multiple sclerosis
Adult: 150 mg once mthly. Missed dose: ≤2 wk: Administer as soon as possible. >2 wk: Skip the missed dose and wait until the next scheduled dose.
Hepatic impairment: Contraindicated.
Pre-existing hepatic disease or hepatic impairment including ALT or AST ≥2 times the upper limit of normal (ULN), history of autoimmune hepatitis.
Special Precautions
Patient w/ previous or current depressive disorders, severe active infection, TB. Pregnancy and lactation. Monitoring Parameters Monitor serum transaminases (ALT and AST) and bilirubin levels prior to initiation, monthly during treatment, and up to 4 mth after last dose.
Adverse Reactions
Hypersensitivity reactions e.g. anaphylaxis, angioedema, urticaria, rash, pruritus), dermatitis, eczema, psoriasis, skin exfoliation, acne, erythema, dry skin, toxic skin eruption; lymphadenopathy, lymphadenitis, non-infectious colitis; nasopharyngitis, upper resp tract infection, pneumonia, bronchitis, viral infection, influenza, laryngitis, tonsillitis, pharyngitis, folliculitis, anaemia, depression, oropharyngeal pain, diarrhoea, pyrexia, increased ALT/AST.
Potentially Fatal: Autoimmune hepatitis; hepatic failure.
Drug Interactions
May reduce the therapeutic effect of live vaccines.
Daclizumab is a humanised monoclonal antibody that blocks interleukin-2 (IL-2) receptor by binding to the α-chain (CD25 subunit) on the surface of activated T-lymphocytes. The precise mechanism by which it exerts therapeutic effects in multiple sclerosis is unknown.
Absorption: Bioavailability: Approx 90%. Time to peak plasma concentration: 5-7 days.
Distribution: Primarily confined to vascular and interstitial spaces; crosses placenta. Volume of distribution: Approx 6.34 L.
Metabolism: Catabolised to peptides and amino acids.
Excretion: Terminal elimination half-life: Approx 21 days.
Subcutaneous: Store between 2-8°C. Protect from light. Do not freeze.
CIMS Class
ATC Classification
L04AC01 - daclizumab ; Belongs to the class of interleukin inhibitors. Used as immunosuppressants.
Disclaimer: This information is independently developed by CIMS based on daclizumab from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in